The potential palliative role and possible immune modulatory effects of low-dose total body irradiation in relapsed or chemo-resistant non-Hodgkin's lymphoma

In a group of 35 patients with relapsed and/or chemo-resistant non-Hodgkin's lymphoma (NHL), low-dose total body irradiation (LTBI) (+involved-field radiotherapy to bulky sites) achieved a complete remission rate of 29%, 2-years progression-free survival of 32% and a median progression-free sur...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2003-10, Vol.69 (1), p.33-36
Main Authors: Safwat, Akmal, Bayoumy, Yasser, El-Sharkawy, Nahla, Shaaban, Khaled, Mansour, Osman, Kamel, Azza
Format: Article
Language:English
Subjects:
Adult
Aged
CD4-CD8 Ratio
Drug Resistance, Neoplasm
Female
Humans
Low-dose total body irradiation
Lymphoma, Non-Hodgkin - immunology
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - radiotherapy
Male
Middle Aged
Non-Hodgkin's lymphoma
Palliative Care
Radiotherapy Dosage
Recurrence
Relapse
Remission Induction
Survival Rate
Toxicity
Treatment results
Whole-Body Irradiation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a group of 35 patients with relapsed and/or chemo-resistant non-Hodgkin's lymphoma (NHL), low-dose total body irradiation (LTBI) (+involved-field radiotherapy to bulky sites) achieved a complete remission rate of 29%, 2-years progression-free survival of 32% and a median progression-free survival of 12 months. The 2-year survival was 42% and the median survival was 17 months. Immuno-staining and flow cytometry of peripheral blood in 14 patients showed that LTBI leads to a significant increase in the percentage of CD4+ cells with a consequent significant increase in the CD4+/CD8+ ratio. High lymphocytic percent and a high percentage of CD4+ cells before LTBI were significantly correlated with longer response duration and overall survival. These data may suggest that the palliative potential of LTBI should be investigated as an alternative to chemotherapy in NHL patients. The pre-treatment percentage of lymphocytes and CD4+ cells may be used as predictors for response to LTBI.
ISSN:0167-8140
1879-0887
DOI:10.1016/S0167-8140(03)00247-0